Multiple Sclerosis Impact Scale

1. Abstract

The Multiple Sclerosis Impact Scale (most notably operationalized as the MSIS-29) is a patient-reported outcome measure (PROM) developed to evaluate the day-to-day physical and psychological burden of multiple sclerosis (MS). Developed by Jeremy Hobart and colleagues in 2001 using combined qualitative methodologies, Classical Test Theory (CTT), and Rasch Measurement Theory (RMT), the instrument captures patient experiences over a two-week recall window. The scale comprises 29 items divided into two discrete subscales: a 20-item Physical Impact Subscale (MSIS-29-PHYS) and a 9-item Psychological Impact Subscale (MSIS-29-PSYCH). In its original iteration, each item is scored on a 5-point Likert scale ranging from 1 (“Not at all”) to 5 (“Extremely”), while version 2 (MSIS-29v2) utilizes a refined 4-point response continuum to resolve category threshold disordering. Psychometric evaluations across diverse multinational cohorts demonstrate high internal consistency, with Cronbach’s alpha exceeding 0.90 for the physical domain and 0.85 for the psychological domain. The instrument exhibits convergent validity with performance-based measures such as the Expanded Disability Status Scale (EDSS) and the Timed 25-Foot Walk (T25FW), as well as generic health-related quality of life measures such as the Short Form-36 Health Survey (SF-36). The MSIS-29 is recognized in clinical trials and neuro-rehabilitation programs for its responsiveness to therapeutic changes and longitudinal neurodegenerative shifts.

2. Keywords

Multiple Sclerosis Impact Scale, MSIS-29, patient-reported outcome measure, health-related quality of life, neuro-disability, psychometrics, physical impact, psychological burden, Rasch measurement theory, neurological assessment

3. Authors

The primary development and initial psychometric validation of the Multiple Sclerosis Impact Scale were spearheaded by a research consortium led by Jeremy C. Hobart (Professor of Clinical Neurosciences and Consultant Neurologist, Plymouth University Peninsula Schools of Medicine and Dentistry, UK). Co-investigators on the foundational development team included:

• Donna L. Lamping, PhD – Health Services Research Unit, Department of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.
• Jennifer A. Freeman, PhD – Faculty of Health, Education and Society, Plymouth University, Plymouth, UK.
• Ray Fitzpatrick, PhD – Department of Public Health, University of Oxford, Oxford, UK.
• Alan J. Thompson, MD, FRCP – Institute of Neurology, University College London (UCL), Queen Square, London, UK.

Subsequent linguistic validations and cross-cultural psychometric adaptations have been conducted worldwide, including the Dutch adaptation published by Erwin L. J. Hoogervorst and colleagues at the Department of Neurology, VU University Medical Center, Amsterdam, Netherlands.

4. Purpose

Multiple sclerosis is an immune-mediated, chronic neuroinflammatory and neurodegenerative disease of the central nervous system characterized by unpredictable relapses and progressive neurological deterioration. Historically, clinical assessments relied primarily on clinician-rated impairment indices, most notably the Kurtzke Expanded Disability Status Scale (EDSS). While the EDSS quantifies neurological impairment—skewed toward ambulatory function at mid-to-high scores—it correlates imperfectly with patient experience, functional restrictions in social contexts, and psychological distress.

Generic health-related quality of life (HRQoL) instruments, such as the SF-36 and the EuroQol 5-Dimension (EQ-5D), provide population-level comparability but may lack responsiveness to the distinct multi-system manifestations of MS, such as transient motor fatigability, fine-motor coordination loss, spasms, neurogenic bladder urgency, and cognitive exhaustion. Hobart and colleagues (2001) designed the MSIS-29 to address this measurement gap.

The core objective of the MSIS-29 is to offer a validated, disease-specific measure sensitive to therapeutic interventions (such as disease-modifying therapies, physical rehabilitation, symptom-targeted pharmacological agents, and psychological therapies) while supporting clinical registries and routine neurological consultations. The scale operationalizes MS-related disability across both motor and psychological spheres, enabling clinicians to identify unaddressed affective distress, fatigue-related functional withdrawal, and fine-motor decay.

5. Psychological Construct

The Multiple Sclerosis Impact Scale measures health-related quality of life and perceived functional disability resulting from MS. Rather than assessing isolated neurological deficits (e.g., reflex asymmetry or visual evoked potentials), the MSIS-29 captures the phenotypic expression of these impairments across daily life activities and emotional functioning over the preceding two weeks.

Physical Impact Subscale (MSIS-29-PHYS; Items 1–20)

The physical subscale encompasses twenty items evaluating limitations in mobility, gross motor capacity, fine motor dexterity, neuromuscular integrity, autonomic stability, and domestic role functioning:

• Gross motor performance and physical demands: Evaluates difficulties handling physically strenuous activities (Item 1), carrying heavy or awkward objects (Item 3), and mobility indoors (Item 5).
• Fine motor coordination and dexterity: Explores upper-limb deficits that interfere with everyday autonomy, such as gripping objects tightly (e.g., opening jars or turning taps, Item 2) and general manual dexterity tasks (Item 15).
• Neuromuscular symptoms: Captures the subjective burden of vestibular and cerebellar disruptions causing balance loss (Item 4), generalized clumsiness (Item 6), muscular stiffness and hypertonia (Item 7), subjective sensations of limb heaviness (Item 8), motor tremors (Item 9), and painful or involuntary muscle spasms (Item 10).
• Autonomy and physiological control: Measures perceived loss of motor control (“Your body not doing what you want it to do”, Item 11), dependency on informal or professional caregivers (Item 12), and autonomic dysfunction—specifically neurogenic urinary urgency (Item 20).
• Temporal pacing and role execution: Evaluates restrictions on domestic leisure and social obligations (Item 13), involuntary domestic confinement (Item 14), occupational cutbacks (Item 16), transportation hurdles (Item 17), compensatory pacing / temporal elongation (“Taking longer to do things”, Item 18), and diminished spontaneity (Item 19).

Psychological Impact Subscale (MSIS-29-PSYCH; Items 21–29)

The psychological dimension comprises nine items evaluating affective distress, mental exhaustion, cognitive efficiency, and existential health-related concerns secondary to living with a fluctuating neurodegenerative condition:

• Somatic malaise and sleep architecture: Evaluates generalized feelings of being unwell (Item 21) and disruptions to restorative sleep (Item 22).
• Cognitive fatigue and mental slowing: Distinguishes somatic muscular fatigue from mental exhaustion (Item 23) and attention deficits or concentration difficulties (Item 27).
• Affective distress and affective lability: Quantifies generalized illness-related apprehension (Item 24), psychic anxiety or tension (Item 25), emotional dysregulation (irritability, annoyance, being easily upset; Item 26), feelings of diminished self-confidence or self-efficacy (Item 28), and depressive symptoms (Item 29).

6. Theoretical Framework

The development of the MSIS-29 is grounded in the World Health Organization’s International Classification of Functioning, Disability and Health (ICF) framework. The ICF model conceptualizes human functioning as an interactive, non-linear continuum involving three interconnected levels: Body Functions and Structures (physiological and anatomical integrity), Activities (individual task execution), and Participation (involvement in life situations), all shaped by environmental and personal contextual factors.

Traditional neurological scales focus largely on the structural impairment level (e.g., demyelination patterns, muscle weakness, visual field loss). The MSIS-29 operates primarily across the Activity Limitation and Participation Restriction nodes of the ICF framework, assessing the real-world operational consequences of those biological lesions. When an individual reports that limb heaviness (an impairment) limits their capacity to prepare meals (an activity limitation) or leads to missing family events (a participation restriction), the instrument captures this downstream impact.

From a psychometric perspective, the MSIS-29 was developed through both classical and modern psychometric methodologies:

• Item Generation: Derived from comprehensive qualitative interviews with individuals with MS, professional expert consensus panels, and literature reviews, ensuring content relevance.
• Classical Test Theory: Applied to establish standard item metrics (item-total correlations, item-difficulty distributions, internal consistency).
• Rasch Measurement Theory: Employed to examine unidimensionality, item invariant scaling, and category probability curves. This work highlighted threshold disordering in the original 5-point response scale, motivating the 4-point structure in MSIS-29v2.

7. Validity

The validity of the Multiple Sclerosis Impact Scale has been established across clinical and research populations worldwide.

Construct and Known-Groups Validity

Known-groups validity has been supported by the scale’s ability to differentiate cohorts based on disease course and disability status. Hobart et al. (2001) demonstrated significant differences in MSIS-29-PHYS scores between primary progressive MS (PPMS), secondary progressive MS (SPMS), and relapsing-remitting MS (RRMS), with progressive subtypes showing higher physical impact scores. Patients with higher neurological impairment as measured by the EDSS (≥ 6.0, indicating reliance on unilateral/bilateral walking aids) show higher MSIS-29-PHYS scores compared to minimally disabled patients (EDSS ≤ 3.0).

Convergent and Discriminant Validity

Correlation patterns with established criterion instruments demonstrate both convergent and discriminant properties:

• The MSIS-29-PHYS correlates strongly with physical health domains of the SF-36 (e.g., Physical Functioning: r = -0.75 to -0.85; Role Physical: r = -0.65 to -0.78), performance-based ambulatory indices (Timed 25-Foot Walk: r = 0.60 to 0.72), and the Hauser Ambulation Index. In contrast, its correlations with the SF-36 Mental Health domain and the Hospital Anxiety and Depression Scale (HADS) are lower (r ≈ 0.35 to 0.45).
• The MSIS-29-PSYCH correlates with psychological scales, demonstrating relationships with the HADS-Depression subscale (r = 0.68 to 0.74), HADS-Anxiety subscale (r = 0.65 to 0.73), and the SF-36 Mental Health dimension (r = -0.70 to -0.78). Its correlation with pure motor velocity metrics (such as the 9-Hole Peg Test or T25FW) is lower (r ≈ 0.20 to 0.35).

Longitudinal Responsiveness and Predictive Validity

Responsiveness statistics show sensitivity to clinical change. In randomized trials evaluating rehabilitation and acute relapse treatments, the MSIS-29-PHYS demonstrates effect sizes (Cohen’s d or Standardized Response Mean [SRM]) ranging between 0.65 and 0.90 following multi-week neuro-rehabilitation interventions. The scale also reflects the accumulation of longitudinal disability, predicting patient-reported employment status changes and care dependency.

8. Reliability

The MSIS-29 shows high reliability across study populations, clinical subtypes, and language adaptations.

Internal Consistency

Internal consistency estimates via Cronbach’s alpha exceed classical research benchmarks across validation studies:

• MSIS-29-PHYS: Reported values typically range from α = 0.91 to 0.97 in both clinical trials and observational cohorts (Hobart et al., 2001; Hoogervorst et al., 2004). Item-total correlations for these 20 items consistently surpass 0.50, ranging between 0.58 and 0.84.
• MSIS-29-PSYCH: Cronbach’s alpha values range from α = 0.86 to 0.92, with corrected item-total correlations exceeding 0.55 across all nine items.

Test-Retest Stability

In stable clinical samples re-evaluated over intervals of 1 to 4 weeks (with no documented relapses or steroid intervention), Intraclass Correlation Coefficients (ICC) demonstrate reproducibility:

• MSIS-29-PHYS: ICCs range from 0.88 to 0.95.
• MSIS-29-PSYCH: ICCs range from 0.82 to 0.90.

Standard Error of Measurement (SEM) and Smallest Detectable Change (SDC) studies report that a change of approximately 8 to 10 points on the transformed 0–100 scale reflects genuine clinical change beyond measurement noise.

9. Factor Analysis

Structural evaluations of the MSIS-29 have explored its underlying factor composition through both classical exploratory/confirmatory factor analyses and modern Rasch analysis.

Exploratory and Confirmatory Factor Analyses (EFA / CFA)

Early exploratory factor analyses (Principal Component Analysis with Varimax and Oblimin rotations) identified two primary factors explaining over 55% of the total variance:

• Factor 1: Loaded on by Items 1 through 20 (Physical Impact), with factor loadings between 0.52 and 0.85.
• Factor 2: Loaded on by Items 21 through 29 (Psychological Impact), with factor loadings between 0.58 and 0.81.

Confirmatory Factor Analysis (CFA) models testing an oblique two-factor structure generally demonstrate good fit across varied international cohorts:

• Comparative Fit Index (CFI) ≥ 0.92 to 0.95
• Tucker-Lewis Index (TLI) ≥ 0.91 to 0.94
• Root Mean Square Error of Approximation (RMSEA) ≈ 0.055 to 0.072
• Standardized Root Mean Square Residual (SRMR) ≤ 0.060

While unidimensional second-order models have been tested, the two-factor oblique model consistently demonstrates superior fit, supporting the reporting of separate physical and psychological subscale scores rather than an undifferentiated total composite.

Rasch Measurement Model Analysis

Rasch analysis conducted on the original 5-point MSIS-29 revealed that respondents had difficulty distinguishing between the intermediate categories 3 (“Moderately”) and 4 (“Quite a bit”), resulting in reversed category thresholds for several items. This observation prompted Hobart and colleagues to develop MSIS-29 Version 2 (MSIS-29v2), which collapses the intermediate response choices into a 4-point response continuum (1 = Not at all, 2 = A little, 3 = A moderate amount, 4 = A lot), restoring monotonic threshold ordering and improving measurement precision.

10. Instrument / Measurement Tool

• Instrument Name: Multiple Sclerosis Impact Scale (MSIS-29)
• Alternative Versions: MSIS-29 Version 1 (5-point scale); MSIS-29 Version 2 (4-point scale); electronic / tablet versions (e-MSIS-29).
• Format: Patient-Reported Outcome Measure (Self-administered questionnaire or structured interviewer-led format).
• Target Population: Adults and older adults diagnosed with clinically definite multiple sclerosis (including RRMS, SPMS, PPMS, and clinically isolated syndrome).
• Recall Period: Past two weeks (14 days).
• Administration Time: Approximately 5 to 10 minutes.
• Total Item Count: 29 items.
  • Physical Impact Subscale (MSIS-29-PHYS): Items 1 to 20.
  • Psychological Impact Subscale (MSIS-29-PSYCH): Items 21 to 29.
• Response Options:
  • Version 1 (Original): 5-point Likert scale: 1 = Not at all, 2 = A little, 3 = Moderately, 4 = Quite a bit, 5 = Extremely
  • Version 2: 4-point Likert scale: 1 = Not at all, 2 = A little, 3 = A moderate amount, 4 = A lot
• Scoring and Transformation:
  • Raw Subscale Scores: Computed by summing item responses within each subscale.
    • MSIS-29-PHYS (Version 1): Minimum raw score = 20; Maximum raw score = 100.
    • MSIS-29-PSYCH (Version 1): Minimum raw score = 9; Maximum raw score = 45.
  • Standardized Linear Transformation (0–100 scale):
    $$\text{Transformed Score} = 100 \times \left( \frac{\text{Observed Score} – \text{Minimum Possible Score}}{\text{Ma\ximum Possible Score} – \text{Minimum Possible Score}} \right)$$
  • Interpretation: Higher transformed scores indicate greater perceived disease impact, functional limitation, and distress.

11. Permissions & Fee and Test Year

The original Multiple Sclerosis Impact Scale (MSIS-29) was introduced in 2001 by Jeremy Hobart and colleagues at University College London and the London School of Hygiene & Tropical Medicine. The primary clinical validation paper appeared in The Lancet (Hobart et al., 2001). Cross-cultural translations followed, including the Dutch adaptation by Hoogervorst and colleagues in 2004.

Copyright and Licensing: The instrument is protected by international copyright held by Plymouth Hospitals NHS Trust / University College London / the authors. Licensing administration, user agreements, and validated language translations are managed through the Mapi Research Trust via its ePROVIDE platform. While available for non-funded academic research and routine non-commercial clinical work upon registration, fees and contractual agreements apply to industry-sponsored clinical trials and commercial research endeavors.

12. References

• Hobart, J., Lamping, D., Fitzpatrick, R., Riazi, A., & Thompson, A. (2001). The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. The Lancet, 358(9290), 1362–1367. https://doi.org/10.1016/S0140-6736(01)06415-2
• Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2004). Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31–36. https://doi.org/10.1212/WNL.60.1.31
• Hoogervorst, E. L. J., Eelen, P., Uitdehaag, B. M. J., & Polman, C. H. (2004). The Dutch version of the Multiple Sclerosis Impact Scale (MSIS-29): A valid and reliable outcome measure. Multiple Sclerosis Journal, 10(4), 415–419. https://doi.org/10.1191/1352458504ms1058oa
• Riazi, A., Hobart, J. C., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2002). Using the SF-36 in multiple sclerosis: Is the form of administration important? Multiple Sclerosis Journal, 8(5), 440–444. https://doi.org/10.1191/1352458502ms838oa
• Rampellini, C., Hobart, J. C., & Cano, S. J. (2014). Enhancing measurement efficiency in MS: The MSIS-29 short-form. Neurology, 82(10 Supplement), P2.188.
• van der Linden, F. A. H., Kragt, J. J., Klein, M., van der Ploeg, H. M., Polman, C. H., & Uitdehaag, B. M. J. (2011). Measuring the impact of multiple sclerosis: Psychometric properties of the Dutch Multiple Sclerosis Impact Scale (MSIS-29). Multiple Sclerosis Journal, 17(8), 1010–1017. https://doi.org/10.1177/1352458511403531

13. Items of the Scale